CN117580826A - Nlrp3炎症小体抑制剂 - Google Patents

Nlrp3炎症小体抑制剂 Download PDF

Info

Publication number
CN117580826A
CN117580826A CN202280045960.2A CN202280045960A CN117580826A CN 117580826 A CN117580826 A CN 117580826A CN 202280045960 A CN202280045960 A CN 202280045960A CN 117580826 A CN117580826 A CN 117580826A
Authority
CN
China
Prior art keywords
amino
phenol
pyrido
pyridazin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280045960.2A
Other languages
English (en)
Chinese (zh)
Inventor
L·A·M·约翰松
H·格拉丁
G·贝尔贡齐尼
H·苏伽马
T·马特苏穆拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
AstraZeneca AB
Original Assignee
Mitsubishi Tanabe Pharma Corp
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, AstraZeneca AB filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN117580826A publication Critical patent/CN117580826A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN202280045960.2A 2021-07-02 2022-07-01 Nlrp3炎症小体抑制剂 Pending CN117580826A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163217970P 2021-07-02 2021-07-02
US63/217970 2021-07-02
PCT/EP2022/068292 WO2023275366A1 (en) 2021-07-02 2022-07-01 Nlrp3 inflammasome inhibitors

Publications (1)

Publication Number Publication Date
CN117580826A true CN117580826A (zh) 2024-02-20

Family

ID=82611090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280045960.2A Pending CN117580826A (zh) 2021-07-02 2022-07-01 Nlrp3炎症小体抑制剂

Country Status (31)

Country Link
US (2) US11970463B2 (cg-RX-API-DMAC7.html)
EP (2) EP4628490A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024523623A (cg-RX-API-DMAC7.html)
KR (1) KR20240031343A (cg-RX-API-DMAC7.html)
CN (1) CN117580826A (cg-RX-API-DMAC7.html)
AR (1) AR126351A1 (cg-RX-API-DMAC7.html)
AU (2) AU2022304254B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023026976A2 (cg-RX-API-DMAC7.html)
CA (1) CA3224513A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003939A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024000565A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240038A (cg-RX-API-DMAC7.html)
DK (1) DK4363406T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000002A (cg-RX-API-DMAC7.html)
EC (1) ECSP24008862A (cg-RX-API-DMAC7.html)
ES (1) ES3054790T3 (cg-RX-API-DMAC7.html)
FI (1) FI4363406T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251513T1 (cg-RX-API-DMAC7.html)
IL (1) IL309680A (cg-RX-API-DMAC7.html)
LT (1) LT4363406T (cg-RX-API-DMAC7.html)
MA (1) MA65277B1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000234A (cg-RX-API-DMAC7.html)
PE (1) PE20250122A1 (cg-RX-API-DMAC7.html)
PL (1) PL4363406T3 (cg-RX-API-DMAC7.html)
PT (1) PT4363406T (cg-RX-API-DMAC7.html)
RS (1) RS67463B1 (cg-RX-API-DMAC7.html)
SI (1) SI4363406T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500441T1 (cg-RX-API-DMAC7.html)
TW (1) TW202321201A (cg-RX-API-DMAC7.html)
UY (1) UY39839A (cg-RX-API-DMAC7.html)
WO (1) WO2023275366A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115417856A (zh) * 2021-09-30 2022-12-02 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2026002229A1 (zh) * 2024-06-28 2026-01-02 长春金赛药业有限责任公司 一种nlrp3抑制剂化合物及其制备方法和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202231281A (zh) * 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4347571B1 (en) 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.
CA3226995A1 (en) * 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250162767A (ko) * 2022-12-28 2025-11-19 아스트라제네카 아베 Nlrp3 인플라마좀 억제제의 결정질 형태, 화학 공정 및 화학적 화합물
CN120418236A (zh) 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
KR20250074627A (ko) * 2023-11-20 2025-05-27 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3을 억제하기 위한 5-클로로-2-(4-((2-하이드록시-2-메틸프로필)아미노)피리도[3,4-d]피리다진-1-일)페놀의 고형 유리염기 형태 및 이의 용도
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026006510A1 (en) * 2024-06-26 2026-01-02 Virginia Commonwealth University Compounds as nlrp3 inhibitors, and compositions and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
CN111315733A (zh) * 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN115279739B (zh) 2020-03-27 2025-07-22 尼科治疗有限公司 取代哒嗪化合物
TW202231281A (zh) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
EP4289823A4 (en) 2021-02-08 2025-02-26 Medshine Discovery Inc. SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
JP2024529839A (ja) 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Nlrp3モジュレーター

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115417856A (zh) * 2021-09-30 2022-12-02 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
CN115417856B (zh) * 2021-09-30 2025-06-27 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2026002229A1 (zh) * 2024-06-28 2026-01-02 长春金赛药业有限责任公司 一种nlrp3抑制剂化合物及其制备方法和应用

Also Published As

Publication number Publication date
JP2024523623A (ja) 2024-06-28
UY39839A (es) 2023-01-31
PL4363406T3 (pl) 2026-01-05
CL2023003939A1 (es) 2024-08-30
ES3054790T3 (en) 2026-02-06
KR20240031343A (ko) 2024-03-07
FI4363406T3 (fi) 2025-12-02
EP4363406B1 (en) 2025-09-10
AU2022304254B2 (en) 2025-06-12
HRP20251513T1 (hr) 2026-01-02
EP4628490A2 (en) 2025-10-08
BR112023026976A2 (pt) 2024-03-12
US12503445B2 (en) 2025-12-23
ECSP24008862A (es) 2024-03-01
SI4363406T1 (sl) 2026-01-30
MA65277B1 (fr) 2025-12-31
AU2022304254A1 (en) 2024-02-08
EP4363406A1 (en) 2024-05-08
AR126351A1 (es) 2023-10-11
AU2025223957A1 (en) 2025-09-18
DK4363406T3 (da) 2025-12-01
EP4628490A3 (en) 2025-12-03
CO2024000565A2 (es) 2024-04-18
US20230110122A1 (en) 2023-04-13
IL309680A (en) 2024-02-01
US11970463B2 (en) 2024-04-30
CR20240038A (es) 2024-05-24
US20240383862A1 (en) 2024-11-21
WO2023275366A1 (en) 2023-01-05
TW202321201A (zh) 2023-06-01
SMT202500441T1 (it) 2026-01-12
RS67463B1 (sr) 2025-12-31
CA3224513A1 (en) 2023-01-05
DOP2024000002A (es) 2024-05-15
PT4363406T (pt) 2025-12-15
MX2024000234A (es) 2024-04-16
LT4363406T (lt) 2025-12-29
PE20250122A1 (es) 2025-01-16

Similar Documents

Publication Publication Date Title
EP4363406B1 (en) Nlrp3 inflammasome inhibitors
RU2753520C2 (ru) Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы
TW201408662A (zh) 二氫嘧啶類化合物及其在藥物中的應用
JP2016510043A (ja) 新規なヌクレオシドホスホロアミデート化合物およびその使用
IL259862A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
CN120584106A (zh) Nlrp3炎性小体抑制剂
CN109715623A (zh) 5-[2-(吡啶-2-基氨基)-1,3-噻唑-5-基]-2,3-二氢-1H-异吲哚-1-酮衍生物及其作为磷脂酰肌醇3-激酶δ和γ的双重抑制剂的用途
WO2023194964A1 (en) Fused pyridazine derivatives as nlrp3 inhibitors
CN114206871B (zh) 1-(6-(甲氧基)哒嗪-3-基)环丙烷-1-甲酰胺衍生物作为自分泌运动因子(atx)调节剂治疗发炎性气道疾病
CN120435457A (zh) Nlrp3炎性小体抑制剂的结晶形式、化学方法和化学化合物
TW202430188A (zh) 作為cx3cr1調節劑的2,4,6-三取代的1,3,5-三𠯤
JP2020536937A (ja) Map4k4阻害剤
JP7587887B2 (ja) Jakキナーゼ阻害剤としての小分子化合物及びその用途
KR102521320B1 (ko) 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물
JP2021529772A (ja) アミノ−ピリミドニル誘導体、その調製プロセス及びそれを含有する医薬組成物
HK40111057A (en) Nlrp3 inflammasome inhibitors
HK40111057B (en) Nlrp3 inflammasome inhibitors
EP4452965A1 (en) Cyclohexane acid derivatives as lpa receptor inhibitors
JP2024095612A (ja) 医薬組成物
EA050566B1 (ru) Ингибиторы инфламмасомы nlrp3
NZ717556B2 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination